J Am Pharm Assoc (2003) 44:161–167CrossRef 13. Elliott ME, Meek PD, Kanous NL et al (2002) Pharmacy-based E7080 chemical structure bone mass measurement to assess osteoporosis risk. Ann Pharmacother 36:571–577PubMedCrossRef 14. Goode JV, Swiger K, Bluml BM (2004) Regional osteoporosis screening, referral, and monitoring program in community pharmacies: findings from Project ImPACT: Osteoporosis. J Am Pharm Assoc (2003) 44:152–160CrossRef 15. Hall LN, Shrader SP, Ragucci KR (2009) Evaluation of compliance with osteoporosis treatment guidelines after initiation of a pharmacist-run osteoporosis service at a family medicine clinic. Ann Pharmacother 43:1781–1786PubMedCrossRef 16. Ho C, Cranney A, Campbell A (2006) Measuring the impact of pharmacist

intervention: results of patient education about osteoporosis after fragility fracture. Can J Hosp Pharm 59:184–193 17. Johnson JF, Koenigsfeld C, Hughell L, Parsa RA, Bravard S (2008) Bone health screening, education, and referral project in northwest Iowa: creating a model for community pharmacies. J Am Pharm Assoc (2003) 48:379–387CrossRef 18. Law AV,

Shapiro K (2005) Impact of a community pharmacist-directed CP673451 in vivo clinic in improving screening and awareness of osteoporosis. J Eval Clin Pract 11:247–255PubMedCrossRef AZD5582 clinical trial 19. MacLaughlin EJ, MacLaughlin AA, Snella KA et al (2005) Osteoporosis screening and education in community pharmacies using a team approach. Pharmacotherapy 25:379–386PubMedCrossRef 20. Nadrash TA, Plushner SL, Delate T (2008) Clinical pharmacists’ role in improving osteoporosis treatment rates among elderly patients with untreated atraumatic fractures. Ann Pharmacother 42:334–340PubMedCrossRef 21. Naunton M, Peterson GM, Jones G (2006) Pharmacist-provided quantitative ultrasound screening for rural women at risk of osteoporosis. Ann Pharmacother 40:38–44PubMed 22. Newman

ED, Hanus P (2001) LY294002 Improved bone health behavior using community pharmacists as educators: the Geisinger health system community pharmacist osteoporosis education program. Dis Manag Health Outcomes 9:329–335CrossRef 23. Riley K, Martin J, Wazny LD (2005) Impact of pharmacist intervention on osteoporosis treatment after fragility fracture: positive effect of pharmacist information program shown in pilot study. Can Pharm J 138:37–43 24. Siow JY, Lai PS, Chua SS, Chan SP (2009) The impact of pharmacist intervention on the use of activated vitamin D in a tertiary referral hospital in Malaysia. Int J Pharm Pract 17:305–311PubMedCrossRef 25. Stroup JS, Rivers SM, Abu-Baker AM et al (2007) Two-year changes in bone mineral density and T scores in patients treated at a pharmacist-run teriparatide clinic. Pharmacotherapy 27:779–788PubMedCrossRef 26. Summers KM, Brock TP (2005) Impact of pharmacist-led community bone mineral density screenings. Ann Pharmacother 39:243–248PubMedCrossRef 27. Peters S, Singla D, Raney E (2006) Impact of pharmacist-provided osteoporosis education and screening in the workplace.